The US Food and Drug Administration recently issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy — bamlanivimab and etesevimab — issued together for treatment of mild to moderate COVID-19.
This therapy is issued to patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization, according to a post on CMS’ website.
CMS identified specific codes for the monoclonal antibody product and specific administration codes for Medicare payment. They are:
- Long descriptor: Injection, bamlanivimab and etesevimab, 2100 mg
- Short descriptor: bamlanivimab and etesevima
- Long Descriptor: intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
- Short Descriptor: bamlan and etesev infusion